FBL4 Activators

FBL4 Activators can be grouped into two categories. The first group includes compounds that indirectly enhance the function of FBL4 by increasing the load of ubiquitinated proteins. These compounds are proteasome inhibitors such as ALLN. By inhibiting the proteasome, these compounds prevent the degradation of ubiquitinated proteins. This increased load of ubiquitinated proteins indirectly promotes FBL4's role in the ubiquitin-proteasome pathway, where it acts as a substrate-recruiting component of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. Eeyarestatin I, an inhibitor of the p97/VCP protein involved in segregating ubiquitinated proteins for degradation, also falls into this group.

The second group includes compounds that enhance FBL4 function by modulating cellular processes related to its activity. Forskolin, an activator of adenylyl cyclase, increases cAMP levels and induces protein kinase activation. This may lead to phosphorylation events that regulate FBL4 activity, thereby enhancing its function in mediating protein degradation through ubiquitination. Okadaic Acid, an inhibitor of protein phosphatases 1 and 2A, also falls into this category. By inhibiting these phosphatases, Okadaic Acid leads to an overall increase in protein phosphorylation, potentially impacting FBL4 activity. Nocodazole, Vinblastine, and Paclitaxel (Taxol), which modulate microtubule dynamics and cause cell cycle arrest, can increase the demand for FBL4's role in protein degradation and cell cycle regulation. Lastly, Chloroquine inhibits lysosomal acidification, impeding the degradation of proteins and potentially increasing the load of proteins for FBL4 to degrade.